ReviewTechnology in cancer research & treatment
Prognostic Biomarkers for Papillary Thyroid Cancer: Reducing Overtreatment, Improving Clinical Efficiency, and Enhancing Patient Experience.
Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision Thyroid Oncology: A Review of Multi-Omics Biomarkers and Spatiotemporal Technologies.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid cancer (PTC), the most prevalent form of thyroid malignancy, is generally indolent but poses a recurrence risk of 10%-15%, leading to a clinical paradox: the need to mitigate recurrence while avoiding overtreatment. Current prognostic frameworks, reliant on anatomical and histopathological factors, often result in inefficient treatment pathways, unnecessary surgical interventions, and increased patient burden. The advent of molecular diagnostics presents a paradigm shift in risk stratification. Implementing preoperative molecular tests could transform PTC management by enabling tailored therapeutic strategies, reducing the need for completion thyroidectomies, optimizing the selection of patients for active surveillance, and refining the use of adjuvant therapies such as radioactive iodine. While genomic alterations such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.